Free tool
FAERS Monitor: Attruby
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 216540 or its brand name (Attruby, Acoramidis Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
370
Serious
87
24% of reports
Hospitalization
49
Death reported
12
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- diarrhoea69
- fatigue29
- dizziness23
- blood creatinine increased21
- abdominal discomfort18
- nausea18
- dyspnoea16
- weight decreased16
- asthenia15
- product dose omission issue15
- abdominal pain upper13
- rash11
- death9
- dysphagia9
- gastrointestinal disorder9
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2025 | 189 |
| 2026 | 181 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,789 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| blood creatinine increasedSignal | 21 | 18.3 | 12.1 | 327 |
| abdominal discomfortSignal | 18 | 6.1 | 3.9 | 72 |
| diarrhoeaSignal | 69 | 6.1 | 4.9 | 297 |
| gastrointestinal disorderSignal | 9 | 5.7 | 3.0 | 31 |
| dysphagiaSignal | 9 | 5.4 | 2.8 | 28 |
| abdominal pain upperSignal | 13 | 3.6 | 2.1 | 22 |
| weight decreasedSignal | 16 | 3.3 | 2.0 | 23 |
| product dose omission issueSignal | 15 | 2.9 | 1.8 | 17 |
| dizzinessSignal | 23 | 2.6 | 1.8 | 22 |
| astheniaSignal | 15 | 2.3 | 1.4 | 10 |
| fatigueSignal | 29 | 2.1 | 1.5 | 17 |
| dyspnoea | 16 | 1.6 | 1.0 | 3 |
| rash | 11 | 1.4 | 0.8 | 1 |
| nausea | 18 | 1.3 | 0.8 | 1 |
| death | 9 | 0.6 | 0.3 | 2 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.